Ikarian Capital, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Ikarian Capital, LLC

  • $573 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$25.5 - $41.42 $4.54 Million - $7.38 Million
178,100 New
178,100 $5.03 Million
Q4 2021

Feb 14, 2022
SELL
$29.21 - $44.64 $1.56 Million - $2.38 Million
-53,370 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$21.26 - $38.85 $1.13 Million - $2.07 Million
53,370 New
53,370 $1.57 Million

Others Institutions Holding CERE

# of Institutions
8
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email